Safety considerations in the psychopharmacology of pediatric bipolar disorder
- 11 July 2019
- journal article
- research article
- Published by Taylor & Francis in Expert Opinion on Drug Safety
- Vol. 18 (9) , 777-794
Abstract
Introduction: The standard of treatment of pediatric bipolar disorder (BPD) often requires life-long psychopharmacological management. Several pharmacological agents are approved by the US FDA for the treatment of pediatric BPD. However, each medication may cause adverse events (AEs). Provider awareness of AE profiles of common pharmacologic agents would serve to better inform patients and families in evaluating and selecting between treatment options. Areas covered: This review focuses on medications that, in our clinical experience, are commonly prescribed for youth with BPD and were evaluated in prospective clinical trials for the treatment of pediatric BPD. This paper highlights acute and long-term AEs described in these studies. Expert opinion: Most medications increase risk of AEs in youth with BPD. Treatment with lithium may lead to thyrotropin elevations, but generally does not cause significant weight gain. Divalproex may lead to weight gain; however, this finding was not consistent in comparison studies with lithium. Olanzapine, risperidone, quetiapine, and asenapine are associated with metabolic abnormalities and weight gain. Studies of ziprasidone, aripiprazole and lurasidone do not suggest significant metabolic AEs. More studies are needed to assess efficacy and safety of medications in managing pediatric BPD. Special focus on long-term maintenance trials is required to further identify long-term AEs in this population.Keywords
Funding Information
- funded
This publication has 52 references indexed in Scilit:
- Efficacy and Safety of Quetiapine in Children and Adolescents With Mania Associated With Bipolar I DisorderThe Journal of Clinical Psychiatry, 2013
- A Randomized Controlled Trial of Risperidone, Lithium, or Divalproex Sodium for Initial Treatment of Bipolar I Disorder, Manic or Mixed Phase, in Children and AdolescentsArchives of General Psychiatry, 2012
- Dosing Strategies for Lithium Monotherapy in Children and Adolescents with Bipolar I DisorderJournal of Child and Adolescent Psychopharmacology, 2011
- A Prospective Open‐Label Trial of Lamotrigine Monotherapy in Children and Adolescents with Bipolar DisorderCNS Neuroscience & Therapeutics, 2010
- A Prospective Open-Label Trial of Extended-Release Carbamazepine Monotherapy in Children with Bipolar DisorderJournal of Child and Adolescent Psychopharmacology, 2010
- Four-Year Longitudinal Course of Children and Adolescents With Bipolar Spectrum Disorders: The Course and Outcome of Bipolar Youth (COBY) StudyAmerican Journal of Psychiatry, 2009
- Long-Term Safety of Divalproex Sodium Extended-Release in Children and Adolescents with Bipolar I DisorderJournal of Child and Adolescent Psychopharmacology, 2009
- The Collaborative Lithium Trials (CoLT): specific aims, methods, and implementationChild and Adolescent Psychiatry and Mental Health, 2008
- Pediatric bipolar disorder: validity, phenomenology, and recommendations for diagnosisBipolar Disorders, 2008
- The Off-Label Use of Clozapine in Adolescents with Bipolar Disorder, Intermittent Explosive Disorder, or Posttraumatic Stress DisorderJournal of Child and Adolescent Psychopharmacology, 2004